We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Transplanted Muscle Cells May Aid Damaged Hearts

By Biotechdaily staff writers
Posted on 28 Nov 2002
A study in which muscle cells were transplanted from the thighs of heart patients into their damaged hearts shows evidence of skeletal muscle cell survival and differentiation into mature muscle fibers, leading perhaps to a way to repair damaged hearts without rejection. More...
The results were presented at the 2002 Scientific Sessions of the American Heart Association in Chicago, IL (USA).

Three patients had cells from their thigh muscles injected into their heart muscle while they awaited a heart transplant, then allowed their old, damaged hearts to be examined for signs of cell growth after they received a new heart. Examination revealed that the injected cells not only survived but also began to form muscle fiber. In addition, the areas where the cells were injected showed an increase in the formation of small blood vessels. Since the muscle cells came from the patients' own bodies, none of the patients experienced an immune reaction to the transplants.

The study is based on the premise that certain kinds of cells can be expanded in culture and maintain their functional characteristics. Instead of stem cells, the study used satellite cells, which occur naturally in muscle and help repair damage by dividing and moving to injured areas. After removing cells from the quadriceps muscle, researchers treated them with enzymes to isolate the satellite cells. These were then grown in a laboratory under carefully controlled conditions to give the cells time to divide and produce 300 million cells.

One arm of the study was conducted at the University of Michigan Health System (U-M, Ann Arbor, USA) and Temple University (Chattanooga, TN, USA). This arm involved patients awaiting a heart transplant or a left ventricular assist device (LVAD). Another arm of the study, conducted at the Arizona Heart Institute (Phoenix, USA; www.azheart.com), examined how well patients tolerated different doses of transplanted muscles cells during heart bypass surgery. Indirect evidence of scar tissue regeneration was noted in these patients.

"These results give us the first indication that muscle cell transplants, even from an entirely different kind of muscle, could one day be used to help repair damaged, failing hearts without danger of rejection,” said Francis Pagani, M.D., Ph.D., head of the heart transplant program at the U-M Cardiovascular Center.




Related Links:
Univ. of Michigan
Temple Univ

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.